Upstream Bio News and Activities
Presence
Upstream Bio is a biotechnology company that develops antibody medicines for severe inflammatory diseases. Its main services focus on drug research and clinical development for patients, healthcare providers, and biopharmaceutical partners.
Upstream Bio products and services overview:
- Antibody therapies
- Drug discovery
- Clinical development
- Inflammatory disease treatments
Revenue: ~$0 million
Employees: 80
Headquarters: Waltham, United States (USA)
Upstream Bio is one of the...
Upstream Bio is a company listed under the stock ticker UPB (US).
Executives
View the org chart displaying its 28 main executives
Most searched biographies at Upstream Bio
- Rand Sutherland, Chief Executive Officer and Director
- Marcella Ruddy, Director
- Daniella Beckman, Director
Popular executive movements at Upstream Bio
- Bryan Johnson has joined the company as Senior Director, Analytical (posted on November 4 2025).
Create your alert
to follow the executive moves at Upstream Bio.
Biotechnology
Upstream Bio has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).
Popular M&A news in Biotechnology
- Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
- The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
- MindRank has just announced a $52 Million fundraising (posted on July 14 2026).
Popular contacts in Biotechnology
News
Press releases by Upstream Bio
- Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 — Sun, 06/14/2026 - 10:00
- Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026 — Mon, 06/08/2026 - 07:00
- Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference — Wed, 06/03/2026 - 07:00
- Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference — Mon, 05/18/2026 - 11:30
- Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights — Wed, 05/13/2026 - 07:01
- Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference — Fri, 04/17/2026 - 07:00
- Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results — Thu, 03/26/2026 - 07:00
- Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting — Sun, 03/01/2026 - 09:45
- Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 — Thu, 02/26/2026 - 07:00
- Upstream Bio to Participate in Upcoming March Investor Conferences — Wed, 02/25/2026 - 07:00
- View more press releases Close
Social media about Upstream Bio
- Upstream Bio on Wikipedia, Google News & Yahoo Finance
- Upstream Bio on LinkedIn, X (Twitter) & YouTube
